Cre8™ EVO
The CID Cre8™ EVO DES provided superior clinical outcomes vs. Onyx™ DES in the independent SUGAR RCT (TLF at 1 year: 7.2% Cre8™ EVO vs. 10.9% Onyx™; p superiority = 0.030)
ENTER
NiTiDES™
The only Self-Expanding DES releasing Sirolimus CE marked has proven “top performance” in the ILLUMINA 2years FIM results (SAFETY: 91.9% Freedom from device related MAE; EFFICACY: 93.1% Freedom from TLR and 83.4% Primary Patency rate).
ENTER
Latest NiTiDES™ data just released at LINC 2025
The "All-Comers SFA study" in very complex patients (>15cm average lesion length; 35% severe calcifications; 48,1% CLI) has been presented at LINC2025 by Dr. Cioppa (Mercogliano - IT). The 1y data have shown NiTiDES™ excellent efficacy (91,5% freedom from TLR) and 0% HALO!
ENTER
Cre8™ EVO
The CID Cre8™ EVO DES provided superior clinical outcomes vs. Onyx™ DES in the independent SUGAR RCT (TLF at 1 year: 7.2% Cre8™ EVO vs. 10.9% Onyx™; p superiority = 0.030)
ENTER
NiTiDES™
The only Self-Expanding DES releasing Sirolimus CE marked has proven “top performance” in the ILLUMINA 2years FIM results (SAFETY: 91.9% Freedom from device related MAE; EFFICACY: 93.1% Freedom from TLR and 83.4% Primary Patency rate).
ENTER
Latest NiTiDES™ data just released at LINC 2025
The "All-Comers SFA study" in very complex patients (>15cm average lesion length; 35% severe calcifications; 48,1% CLI) has been presented at LINC2025 by Dr. Cioppa (Mercogliano - IT). The 1y data have shown NiTiDES™ excellent efficacy (91,5% freedom from TLR) and 0% HALO!
ENTER